🟢 GRAIL is trading 10% up today after FDA panel supported Galleri’s benefit-risk profile

GRAIL is trading 10.21% up at $119.60 after an FDA advisory panel supported Galleri’s benefit-risk profile on September 23, 2026.

• Advisers voted 7–2, with one abstention, that the test’s benefits outweighed its risks; safety passed unanimously, while effectiveness received 6–4 support.
• The nonbinding recommendation improves Galleri’s approval prospects, but the FDA’s final decision remains pending.
• The company-specific catalyst is dominating despite weaker biotechnology and broader market conditions on September 24, 2026.